Thursday, May 07, 2020 11:03:34 AM
Cool Blue Capital/Iliad Research and Trading
Why did these two shareholders reduce their positions in the company so significantly as part of the April 30th, 2020 SEC registration? Not a short, just wanting to understand.
I am not denying that Cytodyn Inc. itself was able to raise funds because when the warrants are exercised, at the $0.50 share price, those shareholders then pay the company the warrant price.
But after they executed the warrants, ALL the shareholders reduced their position in the company. If they really thought this was going to the moon, why not hold the shares?
Cool Blue Capital and Iliad Research and Trading are solely in business to profit from equity trades! Yet they don't even think this is going to go higher than $3.25 a share?
The SEC Document is clear: https://sec.report/Document/0001193125-20-128998/
It says that:
Cool Blue Capital had 21,245,875 shares before the filing and after the filing only owns 606,250. Why did they reduce their position by 97%? Cool Blue Capital only exercised 4,835,625 warrants but registered 15,804,000 common stock to sell.
Iliad Research and Trading LP had 8,800,000 before the filing and after the filing only owns 2,500,000 shares? A 72% reduction. Iliad didn't even exercise any warrants. They registered to sell 6,300,000 common stock shares.
These two shareholders represent a reduction of north of 26 million shares. If they thought it was a sure bet to go above 4.00 even, why not earn the additional $26 million in profit and hold the shares?
Thomas C. Mollick reduced his by 4,500,000 and 64%. He only exercised 2,500,000 warrants and sold 2,000,000 shares.
Every single major shareholder reduced their position. These three were by far the largest reductions.
Why did these two shareholders reduce their positions in the company so significantly as part of the April 30th, 2020 SEC registration? Not a short, just wanting to understand.
I am not denying that Cytodyn Inc. itself was able to raise funds because when the warrants are exercised, at the $0.50 share price, those shareholders then pay the company the warrant price.
But after they executed the warrants, ALL the shareholders reduced their position in the company. If they really thought this was going to the moon, why not hold the shares?
Cool Blue Capital and Iliad Research and Trading are solely in business to profit from equity trades! Yet they don't even think this is going to go higher than $3.25 a share?
The SEC Document is clear: https://sec.report/Document/0001193125-20-128998/
It says that:
Cool Blue Capital had 21,245,875 shares before the filing and after the filing only owns 606,250. Why did they reduce their position by 97%? Cool Blue Capital only exercised 4,835,625 warrants but registered 15,804,000 common stock to sell.
Iliad Research and Trading LP had 8,800,000 before the filing and after the filing only owns 2,500,000 shares? A 72% reduction. Iliad didn't even exercise any warrants. They registered to sell 6,300,000 common stock shares.
These two shareholders represent a reduction of north of 26 million shares. If they thought it was a sure bet to go above 4.00 even, why not earn the additional $26 million in profit and hold the shares?
Thomas C. Mollick reduced his by 4,500,000 and 64%. He only exercised 2,500,000 warrants and sold 2,000,000 shares.
Every single major shareholder reduced their position. These three were by far the largest reductions.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
